AnGes Skips FDA Pre-BLA Meeting, Moves Straight to Filing for Limb-Ischemia Gene Therapy
FDA feedback let AnGes skip a required pre-application meeting and start a staged BLA filing for its HGF gene therapy targeting severe leg ischemia in PAD patients, a procedural green light rather than any read on approval chances.